Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.44 Insider Own19.17% Shs Outstand48.98M Perf Week-22.96%
Market Cap9.81M Forward P/E- EPS next Y-0.46 Insider Trans0.12% Shs Float39.59M Perf Month16.32%
Income-16.63M PEG- EPS next Q-0.11 Inst Own9.88% Short Float / Ratio9.53% / 1.17 Perf Quarter-86.09%
Sales0.00M P/S- EPS this Y18.18% Inst Trans-1.04% Short Interest3.77M Perf Half Y-93.14%
Book/sh-0.06 P/B- EPS next Y14.81% ROA-175.67% Target Price10.00 Perf Year-87.24%
Cash/sh0.03 P/C6.91 EPS next 5Y- ROE-1121.89% 52W Range0.13 - 3.46 Perf YTD-87.79%
Dividend- P/FCF- EPS past 5Y-20.66% ROI- 52W High-94.21% Beta0.23
Dividend %- Quick Ratio0.24 Sales past 5Y0.00% Gross Margin- 52W Low49.48% ATR0.06
Employees43 Current Ratio0.24 Sales Q/Q- Oper. Margin0.00% RSI (14)44.02 Volatility36.49% 22.43%
OptionableYes Debt/Eq- EPS Q/Q85.26% Profit Margin- Rel Volume0.96 Prev Close0.22
ShortableYes LT Debt/Eq- EarningsNov 14 BMO Payout- Avg Volume3.22M Price0.20
Recom1.00 SMA20-12.57% SMA503.04% SMA200-87.84% Volume3,098,415 Change-9.77%
Date Action Analyst Rating Change Price Target Change
Feb-04-21Upgrade Maxim Group Hold → Buy $12
Nov-17-20Downgrade Maxim Group Buy → Hold
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Dec-07-23 08:40AM
Nov-20-23 08:10AM
Nov-17-23 07:00AM
Nov-15-23 01:53PM
07:05AM Loading…
Nov-14-23 07:05AM
Nov-08-23 08:00AM
Nov-07-23 06:00AM
Oct-24-23 07:00AM
Oct-23-23 10:05AM
Oct-18-23 08:01AM
Oct-02-23 07:00AM
Sep-27-23 10:48PM
07:00AM Loading…
Sep-26-23 12:17PM
Sep-25-23 08:13AM
Aug-18-23 08:34AM
Aug-15-23 03:11AM
Aug-14-23 07:05AM
Aug-07-23 04:05PM
Jul-17-23 09:15AM
Jul-12-23 07:00AM
Jul-07-23 07:00AM
Jun-20-23 09:06AM
Jun-16-23 07:00AM
Jun-06-23 06:00AM
May-23-23 11:35AM
May-19-23 07:30AM
08:55AM Loading…
May-18-23 08:55AM
May-17-23 02:41PM
May-15-23 07:05AM
May-09-23 06:00AM
Apr-24-23 07:00AM
Apr-07-23 07:30AM
Apr-05-23 07:46PM
Apr-04-23 09:12AM
Mar-30-23 07:05AM
Mar-27-23 09:15AM
Mar-21-23 08:18AM
Jan-10-23 07:00AM
Jan-05-23 07:30AM
Jan-04-23 07:30AM
Dec-27-22 06:00AM
Dec-12-22 07:00AM
Nov-17-22 06:56AM
Nov-16-22 11:28AM
Nov-14-22 07:05AM
Nov-10-22 11:01AM
Nov-07-22 04:10PM
Oct-20-22 06:00AM
Oct-07-22 12:00PM
Oct-04-22 06:00AM
Sep-15-22 06:00AM
Aug-30-22 08:20AM
Aug-17-22 10:16AM
Aug-15-22 07:05AM
Aug-01-22 06:00AM
May-31-22 06:00AM
May-24-22 07:10AM
May-16-22 08:00AM
May-12-22 08:02AM
May-04-22 06:00AM
May-03-22 06:00AM
May-02-22 06:00AM
Apr-04-22 06:20AM
Mar-28-22 09:00AM
Mar-23-22 12:56PM
Mar-14-22 06:00AM
Feb-28-22 04:09PM
Feb-15-22 07:30AM
Feb-01-22 09:38AM
Jan-27-22 07:00AM
Jan-04-22 07:00AM
Dec-27-21 07:00AM
Dec-13-21 08:52AM
Dec-07-21 07:00AM
Dec-02-21 07:00AM
Nov-29-21 07:30AM
Nov-17-21 05:24AM
Nov-15-21 07:00AM
Nov-08-21 07:00AM
Oct-28-21 06:00AM
Oct-25-21 07:00AM
Oct-18-21 07:30AM
Oct-14-21 07:00AM
Oct-06-21 05:00PM
Oct-04-21 06:00AM
Oct-01-21 06:00AM
Sep-24-21 06:56AM
Aug-06-21 08:02AM
Aug-05-21 07:00AM
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lindborg StacyCo-Chief Executive OfficerSep 01Buy1.7711,50020,402181,500Sep 05 05:16 PM